The roles of SMYD4 in epigenetic regulation of cardiac development in zebrafish by Xiao, Deyong et al.
RESEARCH ARTICLE
The roles of SMYD4 in epigenetic regulation of
cardiac development in zebrafish
Deyong Xiao1☯, Huijun Wang2☯, Lili Hao1☯, Xiao Guo2, Xiaojing Ma2,3, Yanyan Qian2,
Hongbo Chen2, Jing Ma2,3, Jin Zhang1, Wei Sheng2,3, Weinian Shou4*,
Guoying Huang2,3*, Duan Ma1,2*
1 Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, Department of Biochemistry
and Molecular Biology, Collaborative Innovation Center of Genetics and Development, Institutes of
Biomedical Sciences, School of Basic Medical Sciences, Fudan University, Shanghai, China, 2 Shanghai
Key Lab of Birth Defect, Children’s Hospital of Fudan University, Shanghai, China, 3 Pediatric Heart Center,
Children’s Hospital of Fudan University, Shanghai, China, 4 Cardiovascular Developmental Biology Group,
Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN,
United States of America
☯ These authors contributed equally to this work.
* wshou@iu.edu (WS); gyhuang@shmu.edu.cn (GH); duanma@fudan.edu.cn (DM)
Abstract
SMYD4 belongs to a family of lysine methyltransferases. We analyzed the role of smyd4 in
zebrafish development by generating a smyd4 mutant zebrafish line (smyd4L544Efs*1) using
the CRISPR/Cas9 technology. The maternal and zygotic smyd4L544Efs*1 mutants demon-
strated severe cardiac malformations, including defects in left-right patterning and looping
and hypoplastic ventricles, suggesting that smyd4 was critical for heart development. Impor-
tantly, we identified two rare SMYD4 genetic variants in a 208-patient cohort with congenital
heart defects. Both biochemical and functional analyses indicated that SMYD4(G345D) was
pathogenic. Our data suggested that smyd4 functions as a histone methyltransferase and,
by interacting with HDAC1, also serves as a potential modulator for histone acetylation.
Transcriptome and bioinformatics analyses of smyd4L544Efs*1 and wild-type developing
hearts suggested that smyd4 is a key epigenetic regulator involved in regulating endoplas-
mic reticulum-mediated protein processing and several important metabolic pathways in
developing zebrafish hearts.
Author summary
SMYD4 belongs to a SET and MYND domain-containing lysine methyltransferase. In
zebrafish, smyd4 is ubiquitously expressed in early embryos and becomes enriched in the
developing heart at 48 hours post-fertilization (hpf). We generated a smyd4 mutant zebra-
fish line (smyd4L544Efs
1) using the CRISPR/Cas9 technology. The maternal and zygotic
smyd4L544Efs
1 mutants demonstrated a strong defect in cardiomyocyte proliferation,
which led to a severe cardiac malformation, including left-right looping defects and hypo-
plastic ventricles. More importantly, two rare genetic variants of SMYD4 were enriched in
a 208-patient cohort with congenital heart defects. Both biochemical and functional
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analyses indicated that SMYD4(G345D)was highly pathogenic. Using mass spectrometric
analysis, SMYD4 was shown to specifically interact with histone deacetylase 1 (HDAC1)
via its MYND domain. Altered di- and tri-methylation of histone 3 lysine 4 (H3K4me2
and H3K4me3) and acetylation of histone 3 in smyd4L544Efs
1 mutants suggested that
smyd4 plays an important role in epigenetic regulation. Transcriptome and pathway anal-
yses demonstrated that the expression levels of 3,856 genes were significantly altered,
which included cardiac contractile genes, key signaling pathways in cardiac development,
the endoplasmic reticulum-mediated protein processing pathway, and several important
metabolic pathways. Taken together, our data suggests that smyd4 is a key epigenetic regu-
lator of cardiac development.
Introduction
Protein post-translational modifications (PTMs) are critical for the biological function of pro-
teins. Histone modification is a common epigenetic mechanism that plays essential roles in the
regulation of chromatin structure and gene expression. Different types of histone modifica-
tions, which are mediated by a series of specific enzymes, can either enhance or inhibit tran-
scription to regulate specific cellular functions or signaling pathways. SET and MYND
domain-containing proteins (SMYDs) belong to a unique family of histone lysine methyltrans-
ferases. This family is composed of five members, including SMYD1, SMYD2, SMYD3,
SMDY4, and SMYD5. These proteins share a Su(var)3-9, an Enhancer-of-zeste and Trithorax
(SET) domain with lysine-specific methyltransferase activity, a Myeloid, Nervy, and DEAF-1
(MYND) domain, and a tetratricopeptide repeat (TPR) domain, which are involved in pro-
tein-protein interactions [1–3]. Several biochemical studies and functional analyses showed
that SMYDs 1–3 exhibit methyltransferase activities for both histone and non-histone proteins
[3–6]. SMYD members are widely present in multiple cell types, including those of skeletal
and cardiac muscles [7–9]. Genetic ablation of Smyd1 in mice led to defects in right ventricular
development [8,10]. The knockdown of smyd1, smyd2, and smyd3 in zebrafish using mor-
pholino technology also led to cardiac malformation and defects in skeletal and cardiac myofi-
brillogenesis [11–13]. Zebrafish smyd5 was recently reported to play important roles in
hematopoiesis [14]. Our knowledge of the biological function of SMYD4 remains limited. A
previous study found that dSMYD4 was crucial for muscle development in Drosophila [15].
However, the role of SMYD4 in vertebrate development and its underlying molecular mecha-
nism have not yet been analyzed thoroughly.
Congenital heart diseases (CHDs) are the most common birth defects, with an annual inci-
dence of approximately 1% of newborns worldwide [16]. Heart development involves complex
genetic and epigenetic regulation [17–19]. Cardiac-specific ablation of HDAC1 and HDAC2 in
the murine heart led to aberrant gene expression, contributing to defects in cardiac morpho-
genesis and contractility [20], suggesting the critical roles of histone modification and epige-
netic regulation in cardiac development. The significant enrichment of mutations in genes
encoding chromatin modifiers in patients with CHDs provided further evidence to support
this notion [21,22].
In this study, we analyzed smyd4 expression in zebrafish embryos and generated a smyd4
loss-of-function mutation (smyd4L544Efs
1) using the CRISPR/Cas9 genome editing technology.
We demonstrated that smyd4 is critical for cardiac malformation in zebrafish development.
Two rare missense SMYD4 variants were identified in patients with CHDs. Both in vitro bio-
chemical assays and in vivo functional analyses strongly suggested that the variant SMYD4
SMYD4 in cardiac development
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(G345D)was pathogenic. Our data suggested that smyd4 functions as a histone methyltransfer-
ase and, by interacting with HDAC1, also serves as a potential modulator for histone acetyla-
tion. Transcriptome and bioinformatics analyses of the differentially expressed genes in
developing hearts isolated from maternal and zygotic smyd4L544Efs
1 (MZsmyd4L544Efs
1)
mutant and normal control embryos showed a significant enrichment of the key genes
involved in cardiac development and contractile function, and the endoplasmic reticulum-
mediated protein processing pathway and several important metabolic pathways. Taken
together, our results suggest that smyd4, in association with hdac1, is an important epigenetic
regulator of these critical pathways during zebrafish cardiac development.
Results
smyd4 expression is specifically enriched in the developing heart
To determine the smyd4 mRNA levels in early to late zebrafish embryos, we performed a
qRT-PCR analysis on embryos at the single-cell (0.2 hours post-fertilization (hpf)), 64-cell (2
hpf), blastula (4 hpf), mid-gastrula (8 hpf), late-gastrula (10 hpf), early primordium (24 hpf),
long pectoral (48 hpf), and protruding mouth stage (72 hpf) stages (Fig 1A). We found that
smyd4 transcripts were highly present in the single-cell stage, suggesting that a large amount of
smyd4 was present as maternal transcripts. Zygotic smyd4 transcription peaked at the blastula
stage and was followed by downregulation in the gastrula stage, indicating the role of this tran-
script in zebrafish early development. The overall expression levels of smyd4 were significantly
further downregulated at 48 hpf and followed by a quick reactivation of expression at 72 hpf.
We then used whole-mount in situ hybridization to determine the spatio-temporal expression
pattern of smyd4 in developing zebrafish embryos. As shown in Fig 1B–1E, smyd4 was ex-
pressed ubiquitously in mid- and late-gastrula embryos; the highest level of expression was
found at the polster in late-gastrula embryos (Fig 1D and 1E). By 24 hpf, smyd4 transcripts
were found to be enriched in the developing heart and blood vessel (Fig 1F and 1G) and
became more restricted to the cardiovascular system at 48 hpf (Fig 1H–1M). Interestingly, the
developing ventricle had a significantly higher level of smyd4 expression than the atrium (Fig
1J and 1K), suggesting its role in cardiac development. The reactivation of smyd4 expression at
72 hpf appeared not to be cardiac specific (Fig 2F).
smyd4-deficient zebrafish is generated by using the CRISPR/Cas9
technology
To determine the biological function of smyd4, we generated smyd4-deficient zebrafish using
the CRISPR/Cas9 technology. Three sgRNAs were designed to target different exons of smyd4
that contribute to the ZMYND, C-terminal TPR2, and SET domains. We were able to generate
an 11-nt insertion in exon 6 that was targeted by sgRNA3 (Fig 2A). As shown in Fig 2B, the
sgRNA3 targeted sequence is well conserved from zebrafish to humans. Sequencing analysis
confirmed this 11-nt insertion, which led to a frameshift at amino acid 545 (smyd4L544Efs
1)
(Fig 2C and 2D and S1 Fig). This frameshift mutation yielded a premature stop codon (TAA),
as indicated by the asterisk in Fig 2C, giving rise to a truncated mutant protein that lacks
the entire C-terminus containing the TPR2 domain (Fig 2D). qRT-PCR and in situ hybridiza-
tion analyses demonstrated that the smyd4 mRNA transcript was completely abolished in
MZsmyd4L544Efs
1 embryos (Fig 2E and 2F). The lack of the smyd4 mRNA transcript was likely
due to the well-known effect of nonsense mutation-mediated degradation (NMD) [23], a pro-
cess common to frameshift mutations. Thus, we concluded that smyd4L544Efs
1 was a loss-of-
function mutation. To better analyze the cardiac defects in MZsmyd4L544Efs
1 mutants, we
SMYD4 in cardiac development
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Fig 1. Quantitative RT-PCR and whole-mount in situ hybridization and qRT-PCR analyses of smyd4 expression in zebrafish early
embryogenesis. (A) The overall expression levels of smyd4 at 0.2, 2, 4, 8, 10, 24, 48 and 72 hpf were analyzed using qRT-PCR. smyd4 displayed its
highest expression levels during the blastula stage (4 hpf) and was significantly decreased at 48 hpf. At 72 hpf, there was a quick reactivation of smyd4
expression. (B-C) During the mid-gastrula stage (8 hpf), smyd4 was ubiquitously expressed in the mid-gastrula embryo (8 hpf). (D, E) smyd4 was
expressed ubiquitously at 10 hpf, with the highest expression levels found at the polster. (F, G) smyd4 was abundant in the heart and blood vessel at
24 hpf. (H-M) Lateral and frontal view of smyd4 expression at 48 hpf. smyd4 became more enriched in the developing hearts at 48 hpf, and the
SMYD4 in cardiac development
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crossed the smyd4L544Efs
1 line with the cardiomyocyte-specific transgenic reporter line Tg
(cmcl2:GFP). The entire work presented here was performed using this bi-genic line
(smyd4L544Efs
1;cmcl2:GFP) with Tg(cmcl2:GFP) as a normal control, unless otherwise indi-
cated in the text.
The smyd4 deficiency leads to abnormal cardiac development
Using the heterozygous breeding scheme, we were able to create heterozygous and homozy-
gous smyd4L544Efs
1 mutant and wild-type embryos. First, we analyzed the survival of
smyd4L544Efs
1 homozygous mutants and found no early lethality in these mutants, as the total
amount of surviving smyd4L544Efs
1 homozygous mutants reached 25% among all three geno-
types, which matched the normal Mendelian ratio. These homozygous mutants appeared nor-
mal in terms of growth and reproductivity. However, when examining these mutants, we
observed a slight increase in embryos with abnormal cardiac situs ambiguus in smyd4L544Efs
1
homozygous (6 out of 14, 43%) and heterozygous (17 out of 48, 35%) mutants compared to the
number of wild-type embryos (2 out of 10, 20%) (S2 Fig). As situs ambiguus is highly relevant
for defects in early patterning, this finding prompted us to speculate that the reduced but
remaining maternal smyd4 transcripts in heterozygous females might contribute to the
reduced severity of the resulting phenotype. Therefore, we established a homozygous breeding
scheme to eliminate the effect of maternal smyd4 transcripts.
The MZsmyd4L544Efs
1 embryos from the homozygous breeding scheme displayed severe
pericardial edema (Fig 3A and 3B) and/or congested blood flow in the ventral veins (Fig 3A
and 3B), suggesting prominent cardiac defects or dysfunctions associated with the
MZsmyd4L544Efs
1 embryos. The cardiac defects were analyzed carefully. Major defects
included a significantly smaller ventricular size and anomalies of cardiac left-right asymmetric
patterning or looping in approximately 60% of MZsmyd4L544Efs
1 embryos at 72 hpf (Fig 3C
and 3G), such as situs ambiguus (straight heart tube) and situs inversus (D-loop heart tube)
(Fig 3C). The 3D-reconstruction of confocal images of 96 hpf hearts further confirmed this
looping defect (Fig 3F and S1 and S2 Movies), as well as hypoplastic ventricles with less trabe-
culated myocardial structures in the MZsmyd4L544Efs
1 hearts (Fig 3F and 3G). The number of
cardiomyocytes on the largest section plane of the MZsmyd4L544Efs
1 mutant ventricle was
found significantly reduced when compared to the comparable section plane of wild-type con-
trol hearts (S3 Fig and Fig 3H), suggesting a great reduction of total number of cardiomyocytes
in MZsmyd4L544Efs
1 hearts. To determine whether reduced cell number was due to the
decreased cellular proliferative activity, we used p-H3 and PCNA immune reactivities to
respective antibodies as the indicators for the level of cell proliferative activities in mutant
developing hearts. As shown in Fig 4A and S4 Fig, MZsmyd4L544Efs
1 mutant cardiomyocytes
had a dramatically reduced level in cellular proliferation when compared to wild-type controls.
In addition, we also evaluated the levels of apoptosis in mutant hearts and we found no evi-
dence of increased level of apoptotic cell in MZsmyd4L544Efs
1 mutant hearts (S5 Fig).
As adults, these MZsmyd4L544Efs
1 mutants had abnormal gross cardiac morphologies and
histologies, typically with less trabecular myocardia and sometimes with a dramatically
increased thickness of the ventricular compact wall (Fig 4B and 4C). Despite these cardiac
defects, we observed no apparent defects in skeletal muscle development in MZsmyd4L544Efs
1
mutants examined at 48 and 72 hpf (S6 Fig), suggesting that smyd4 is lesser important than
smyd1 in vertebrate muscle development [11].
ventricle had a higher expression level than that in the atrium. A smyd4 sense probe was used as the negative control for the in situ hybridization
analysis.
https://doi.org/10.1371/journal.pgen.1007578.g001
SMYD4 in cardiac development
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SMYD4 interacts with HDAC1, and altered histone modification occurs in
MZsmyd4L544Efs
1
As shown in Fig 5A, SMYD4 was localized to both the nucleus and cytoplasm. To determine
the biochemical function of SMYD4, flag-tagged SMYD4 (SMYD4flag) was first overexpressed
in the HL-1 mouse cardiomyocyte cell line, followed by immunoprecipitation and mass spec-
trometric analysis to identify its interacting proteins. HDAC1 was identified as one of the
major proteins to interact with SMYD4 (Fig 5B). This finding was further confirmed by Co-
IP/western blotting analysis using a HEK293T cell line in which both SMYD4flag and HA-
tagged HDAC1 (HDAC1HA) were co-overexpressed (Fig 5C). There are four functional
domains in SMYD4. Two TPR domains are located at the N- and C- termini, an MYND
domain can mediate interactions with partner proteins, and a SET domain functions as a
methyltransferase. To determine the functional domain that was responsible for the SMYD4/
HDAC1 interaction, as shown in Fig 5D and 5E, we generated several mutations in SMYD4
with different combinations of deletions in the SMYD4 protein and co-expressed these
mutants with HDAC1 in HEK293T cells. We were able to use Co-IP/western blotting assays to
demonstrate that the MYND domain was responsible for the interaction between SMYD4 and
HDAC1.
To confirm the biochemical activities of SMYD4 as a methyltransferase and as a functional
partner of HDAC1 in histone modification, we analyzed the changes in both histone methyla-
tion and acetylation modifications in the MZsmyd4L544Efs
1 embryos. As shown in Fig 5F and
5G, di- (me2) and tri-methylation (me3) at the lysine 4 site (K4) of histone 3 (H3) were signifi-
cantly reduced, and mono-methylation of lysine 4 (H3K4me) was increased, while other lysine
residues (i.e., K9 and K27) were not affected, suggesting that SMYD4 was specifically involved
in H3K4 methylation. Interestingly, the acetylation of lysines 4, 9, 14, and 27 was dramatically
reduced in the MZsmyd4L544Efs
1 mutants examined at 48 hpf (Fig 5F and 5G). This finding
suggested that SMYD4 is a critical part of the HDAC1 functional complex and may function
as an important negative regulator of HDAC1-mediated histone 3 modification and epigenetic
regulation. Taken together, these data indicate that SMYD4 is a functional methyltransferase
specific for H3K4 methylation and a functional partner of HDAC1 for regulating H3
acetylation.
Rare SMYD4 variants associated with CHD patients
We used Target Exome Sequencing (TES) and screened a cohort of 208 patients with CHDs
for potential genetic variants of SMYD4. The patient information is summarized in S1 Table
and S2 Table. Two rare missense variants (c.1034G>A, p. G345D and c.1736G>A, p. R579Q)
were identified and confirmed by Sanger sequencing in two individual patients (Fig 6A and
6B). The variants were not recorded in the 1000G database or in our internal whole-exome
sequencing database generated from more than 3,500 patients without CHDs. The frequencies
of G345D and R579Q in the EXAC database are 1/121,404 and 3/120,896, respectively. G345D
was identified in a patient who was diagnosed with DCRV/VSD, and R579Q was identified in
a patient with TOF (S3 Table). Both sites were evolutionally conserved from zebrafish to
Fig 2. The generation of smyd4–deficient zebrafish using the CRISPR/Cas9 technology. (A) Schematic diagram of the smyd4 gene structure and the sgRNA3
sequence for the exon 6 targeting site. The sgRNAs were injected into the embryos with Cas9 mRNA at the single-cell stage; (B) The targeting site of sgRNA3 was
well-conserved from zebrafish to humans; (C) Sanger sequencing confirmed the insertion mutation (c.1629_1630inGAATAATACTG; p.Leu544Glufs1); (D) A
schematic diagram of the insertion mutation. The smyd4 protein contains four functional domains: two TPR domains (green), one MYND domain (yellow), and one
SET domain (purple). The insertion mutation created a truncated mutant protein that lacks the entire C-terminus, which contained the key functional domain TPR2;
(E) qRT-PCR confirmation that smyd4 expression is significantly decreased in MZsmyd4L544Efs
1 embryos; (F) Whole-mount in situ hybridization analysis confirmed
the loss of smyd4 expression in MZsmyd4L544Efs
1 embryos at 72 hpf.
https://doi.org/10.1371/journal.pgen.1007578.g002
SMYD4 in cardiac development
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Fig 3. Phenotypical analyses of MZsmyd4L544Efs
1 embryos. (A) Representative images of the MZsmyd4L544Efs
1 and control embryos at 48 hpf, exhibiting congested
blood flow in the ventral vein; (B) Representative images of the MZsmyd4L544Efs
1 and control embryos at 96 hpf, displaying severe pericardial edema; (C)
Representative images of the MZsmyd4L544Efs
1 and control hearts at 72 hpf, demonstrating abnormal cardiac morphology and left-right looping defects; (D)
Significantly more MZsmyd4L544Efs
1 embryos had abnormal cardiac development than control fish Tg (cmcl2:GFP) (61% ± 4.0% mutants vs. 14% ± 4.6% controls,
n = 100, p< 0.01); (E) Comparison of left-right patterning defects in the MZsmyd4L544Efs
1 (n = 100) and control (n = 100) embryos (green: normal L-loop; blue:
straight; dark blue: D-loop). Only 10% of the control embryos showed an abnormal “straight” cardiac left-right asymmetry pattern. However, 48% of MZsmyd4L544Efs
1
embryos exhibited a “straight” left-right asymmetry pattern, and 11% showed a “D-loop” left-right asymmetry pattern; (F) Representative confocal images of the
ventricular wall and 3D re-construction images of the MZsmyd4L544Efs
1 and control hearts at 96 hpf. The confocal scanned images demonstrated hypoplastic wall with
significant reduction of trabeculation in MZsmyd4L544Efs
1 ventricle when compared to the wild-type control ventricle. The 3D-reconstruction of the hearts confirmed
left-right looping defects in MZsmyd4L544Efs
1 hearts (For a better view of 3D-structures, see supplemental material S1 and S2 Movies). (G) Histological sections and
H&E staining images of the MZsmyd4L544Efs
1 and control hearts at 96 hpf, demonstrating abnormal ventricular walls and reduced trabeculation; (H) The quantitative
analysis of the number of cardiomyocytes in the ventricle displayed that MZsmyd4 L544Efs
1 had significantly reduced cardiomyocytes (p<0.01, ).
https://doi.org/10.1371/journal.pgen.1007578.g003
Fig 4. Phenotypical analyses of MZsmyd4L544Efs
1 embryos. (A) The p-H3(S10) immunofluorescence staining showed decreased cell proliferative activity in
MZsmyd4L544Efs
1 cardiomyocytes at 48 hpf. The number of p-H3 (S10) positive cells in the MZsmyd4L544Efs
1 ventricles was significantly decreased when
compared to the control group (p<0.01, ); (B) The abnormal ventricular morphology of the adult MZsmyd4L544Efs
1 hearts compared to the morphology of
control adult hearts; (C) Histological sections and H&E staining images of the adult MZsmyd4L544Efs
1 and control hearts, demonstrating significant thickening of
the compact ventricular wall. (The red arrows showed that in the similar compact zone of the ventricle). The quantitative analysis displayed that the thickness of
the ventricle compact zone was significantly increased in adult MZsmyd4 L544Efs
1 hearts compared to Tg(cmcl2:GFP) (p<0.05, ).
https://doi.org/10.1371/journal.pgen.1007578.g004
SMYD4 in cardiac development
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humans (Fig 6C). Both variants (G345D and R579Q) were predicted to be highly pathogenic
and harmful by SIFT, PolyPhen2 and MutationTaster. Based on 3D-computational structure
prediction using the SWISS MODEL, as shown in Fig 6D and 6E, both mutations led to signifi-
cant changes in protein structure compared with that of the wild-type SMYD4. To confirm the
pathogenicity of the variant SMYD4(G345D), Co-IP/western blotting assays were performed,
and we found that the biochemical interaction between SMYD4(G345D) and HDAC1 was
greatly attenuated compared to the interaction between SMYD4 and HDAC1 in HL-1 cells
(Fig 6F and 6G), consistent with the predicted alteration of protein structure and function in
SMYD4(G345D).
Functional confirmation of SMYD4(G345D) as a pathogenic mutation
To confirm SMYD4(G345D) as a pathogenic mutation, we performed gain-of-function trans-
genic overexpression experiments by injecting wild-type smyd4 and smyd4(G295D)mRNA
into normal Tg(cmcl2:GFP) embryos (Fig 7A and 7C). Based on the amino acid sequences of
zebrafish smyd4 and human SMYD4, we generated smyd4(G295D)mutant cDNA, which was
equivalent to human SMYD4(G345D) (Fig 6C and S7 Fig). We found that the smyd4(G295D)
mRNA caused significantly more embryos with severe heart defects (e.g., D-loop and tubular
hearts) than wild-type smyd4 mRNA (Fig 7A and 7C), suggesting that SMYD4(G345D)was
harmful to cardiac development.
To further confirm the effects of this mutation, we performed rescue experiments by ana-
lyzing and comparing the ability of mutant SMYD4(G345D) and wild-type SMYD4 to rescue
the abnormal cardiac phenotypes of MZsmyd4L544Efs
1 mutants. We injected smyd4 wild-type
and smyd4(G295D)mutant mRNAs into MZsmyd4L544Efs
1 single-cell embryos harvested from
the homozygous breeding scheme described above. As shown in Fig 7B and 7C, wild-type
smyd4 mRNA significantly reduced the number of embryos with malformed hearts compared
to the number in the MZsmyd4L544Efs
1 mutant group, which indicates a partial but significant
rescue phenotype for the wild-type smyd4 mRNA. In contrast, the smyd4(G295D)mRNA not
only failed to rescue MZsmyd4L544Efs
1 but also significantly increased the number of embryos
with malformed hearts and severe cardiac defects, such as tubular hearts (Fig 7B and 7C), fur-
ther confirming that the smyd4(G295D)mutation is pathogenic. Taken together, our data
implied that human SMYD4(G345D)was deleterious for heart development and a CHD-caus-
ing genetic variant.
Abnormal cardiac gene expression profiling of MZsmyd4L544Efs
1 hearts
Given the severe cardiac defects and abnormal histone modifications in the MZsmyd4L544Efs
1
embryos, we anticipated a large number of gene alterations in MZsmyd4L544Efs
1 mutant hearts.
We performed RNA-seq analysis, comparing normal and MZsmyd4L544Efs
1 hearts harvested at
72 hpf. As shown in Fig 8, a total of 3,856 differentially expressed (DE) genes were identified in
Fig 5. SMYD4 interacts with HDAC1. (A) Immunofluorescence staining and representative confocal images of the sub-cellular localization of SMYD4 in HL-1
cells. SMYD4 was found in both the nucleus and cytoplasm. The experimental groups without primary anti-SMYD4 antibody incubation served as negative
controls; (B) Co-IP/western blotting analysis to confirm the interaction between SMYD4 and HDAC1. SMYD4flag was overexpressed in HL-1 cells. The cell
extracts were immunoprecipitated with an anti-FLAG affinity gel, followed by western blotting analysis; (C) The interaction between SMYD4 and HDAC1 was
further confirmed by Co-IP/western blotting analysis in HEK293T cells; (D-E) Using a Co-IP/western blotting assay to map the domains in SMYD4 that are
responsible for the interaction with HDAC1. The MYND domain of SMYD4 was found to be critical for this interaction; (F) Aberrant histone modifications in
MZsmyd4L544Efs
1 embryos at 48 hpf. Specifically, H3K4me2 and H3K4me3 were significantly reduced, and H3K4me was increased, while H3K9me3 and
H3K27me3 were not affected, suggesting that SMYD4 is a H3K4-specific methyltransferase. H3K4ac, H3K9ac, H3K14ac, and H3K27ac were significantly
abolished in MZsmyd4L544Efs
1 mutants, suggesting the increased activity of HDAC1 in MZsmyd4L544Efs
1 mutants and confirming SMYD4 as an important
negative regulator of HDAC1 function; (G) The semi-quantitative analysis of the histone modifications changes in MZsmyd4L544Efs
1 mutants. (p<0.05 , p<0.01
).
https://doi.org/10.1371/journal.pgen.1007578.g005
SMYD4 in cardiac development
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MZsmyd4L544Efs
1 hearts. Among those genes, 2,648 genes were upregulated, and 1,208 genes
were downregulated (Fig 8A). Not surprisingly, some important genes that were highly rele-
vant to cardiac development were altered, which included the genes involved in cardiac muscle
contraction (upregulated: 10; downregulated: 22) and key cardiac signaling pathways, such as
the canonical Wnt signaling pathway (upregulated: 36, downregulated: 10) and the Hedgehog
signaling pathway (upregulated: 15, downregulated: 3) (Fig 8B). To investigate whether this
altered transcriptional profile was associated with specific pathways or biological processes, we
performed KEGG pathway analysis, which indicated that the upregulated genes were enriched
in the endoplasmic reticulum-mediated protein processing pathway in the Biological Process
domain (Fig 8C) and the downregulated genes were enriched in several metabolic pathways,
including carbon metabolism and the glycolysis/gluconeogenesis pathway (Fig 8D). Gene
ontology (GO) analysis of the upregulated genes also revealed major terms in cellular meta-
bolic processes, in which 975 genes were involved. A GO term analysis of the downregulated
genes revealed the enrichment of a large number of genes in the organonitrogen compound
metabolic process (185 genes), the ATP metabolic process (49 genes) and the glycosyl com-
pound metabolic process (55 genes) (Fig 8E). This finding provided an important hint that
smyd4/hdac1-mediated epigenetic regulation likely occurred via the control of endoplasmic
reticulum-mediated protein processing and several key metabolic pathways in the heart during
zebrafish development.
Discussion
SMYDs are a family of unique lysine-histone methyltransferases that contain the well-con-
served SET and MYND domains, as well as two TPR domains. The biological functions of
SMYDs are largely unknown. By generating smyd4 mutant zebrafish using the CRISPR/Cas9
technology, we have shown that smyd4 is indispensable for cardiac development. This finding
is consistent with the observation that ubiquitously expressed smyd4 in early zebrafish
embryos becomes more enriched to zebrafish developing hearts at 48 hpf during embryogene-
sis, despite the fact that gross expression levels are reduced dramatically at this stage, which is
followed by a quick up-regulation of smyd4 expression in embryos at 72 hpf (Fig 1A). These
are critical stages, in which the newly formed heart switches from the cardiac morphogenic
pathway to cardiac maturation pathways to eventually form a normal functional heart.
There are several major cardiac defects in the MZsmyd4L544Efs
1 mutants, including the
defects in left-right patterning and looping, and the hypoplastic ventricular walls in the devel-
oping hearts. Furthermore, the cell proliferative activities in MZsmyd4L544Efs
1 developing ven-
tricles are significantly decreased, which likely leads to the hypoplastic ventricle. In adults, the
thickening of the ventricular compact wall that is seen in some mutant hearts is likely a malad-
aptation of compromised cardiac function due to cardiac developmental defects.
Considering smyd4 shares similar protein structure and enzymatic activities with other
SMYD family members, genetic and functional redundancy may occur in MZsmyd4L544Efs
1
Fig 6. Rare variants in SMYD4 are associated with CHD patients. (A) Schematic diagram of the human SMYD4 gene. SMYD4 is
composed of eleven exons, and two rare missense variants (c. 1034G>A p.G345D and c. 1736G>A p.R579Q) located in exon 5 and 6,
respectively, were identified in two CHD patients from a 208-patient cohort; (B) The variants G345D and R579Q are located at the edge of
two functional domains, the MYND and SET domains, respectively; (C) Sanger sequencing confirmed the variants. Both variants were
found at a site that is highly conserved from zebrafish to humans; (D) Predicted 3D structure of the wild-type and mutant SMYD4 proteins.
The structures of both mutant proteins are significantly changed (The arrows pointing the location of the mutant amino acid); (E)
Comparison of the structures at the mutation sites between wild-type SMYD4 and the two mutants. The structures of the mutant amino
acids are completely changed; (F) Co-IP/western blotting assays revealed the attenuated interaction between SMYD4(G345D) and HDAC1
in HL-1 cells; (G) The semi-quantitative analysis of the Western blotting results demonstrated that the G345D mutant SMYD4 protein
significantly disrupted the interaction with HDAC1 compared to the wild-type SMYD4 protein (p<0.01, ).
https://doi.org/10.1371/journal.pgen.1007578.g006
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Fig 7. SMYD4(G345D) contributes to cardiac abnormalities. (A) Representative cardiac morphology of wild-type embryos
injected with either wild-type smyd4 or smyd4(G295D) mRNAs; (B) Representative cardiac morphology of MZsmyd4L544Efs
1
embryos injected with either wild-type smyd4 or smyd4(G295D); (C) Summary of the observations from (A) and (B). A total of 50 fish
were screened.
https://doi.org/10.1371/journal.pgen.1007578.g007
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Fig 8. RNA-seq and bioinformatics analysis of MZsmyd4L544Efs
1 hearts. RNA-seq analyses were performed with Tg(cmcl2:GFP) and MZsmyd4L544Efs
1 hearts at 72
hpf; (A) A volcano plot demonstrated that a total of 3,856 genes were differentially expressed in MZsmyd4L544Efs
1 hearts (upregulated: 2,648, downregulated: 1,208); (B)
A heat-map showed that genes involved in cardiac development signaling pathways, including Wnt signaling (upregulated: 36, downregulated: 10), Hedgehog signaling
(upregulated: 15, downregulated: 3), the metabolism pathway (upregulated: 210, downregulated: 154), and cardiac muscle contraction (upregulated: 10, downregulated:
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mutants. It has been shown that smyd1b mutants display a similar pericardial edema and
congestive blood circulation [24]. The morpholino knock-down of another SMYD family
member smyd3 in zebrafish embryos also produces cardiac looping defects [13]. Both of these
prior studies suggest potential genetic interactions and/or redundancies among these family
members in zebrafish heart development. Some variations in the cardiac defects as well as cer-
tain degrees of varying severity of cardiac defects among the mutant embryos further support
this notion. However, it is also clear that each member of SMYD family has its unique func-
tion. For example, myofibril disorganization in skeletal muscle are only seen in smyd1b
mutants [24]. We have not observed any such a defect in MZsmyd4L544Efs
1 mutants, suggesting
that the function of smyd4 is more relevant to cardiac development in zebrafish.
Our observations strongly suggest that smyd4 plays an important function in cardiac devel-
opment. This conclusion is also supported by our human genetic study, which identified two
rare SMYD4 variants in a 208-patient cohort with CHDs. The data obtained after the overex-
pression of mutant smyd4(G295D) and from rescue experiments in which smyd4(G295D)
mRNA was injected into MZsmyd4L544Efs
1 mutants strongly indicates that the human variant
SMYD4(G345D) is pathogenic, further suggesting SMYD4 as a genetic contributor to CHDs.
This finding indicates the importance of including SMYD4 in CHD genetic screening panels
in the future.
One of our key findings is that SMYD4 interacts with the major histone modification
enzyme and epigenetic regulator HDAC1 via the well-conserved MYND domain. Our finding
is consistent with the previous finding that dSmyd4 can interact with dHDAC1 in Drosophila
muscle development [15]. The MYND domain is known for its role in protein-protein interac-
tions and was previously shown to recruit the HDAC complex to regulate gene expression
[25]. The mutation in SMYD4(G345D) is located at the edge of the MYND domain and
between the MYND and SET domains. Our biochemical data show that SMYD4(G345D) has
a dramatically reduced ability to interact with HDAC1. Although the TPR domains are still
poorly understood, previous studies suggest that the C-terminal TPR2 domain is vital for
methyltransferase activity and protein-protein interactions [3,26]. The TPR2 domain of
SMYD2 is indispensable for its interaction with HSP90, which proved to be critical for titin fil-
ament organization [12,27]. Currently, we are in the process of generating smyd4-tpr2del
mutant zebrafish similarly using the CRISPR/Cas9 technology to further investigate the role of
TPR2 in smyd4 biological function.
SMYDs 1 and 3 catalyze mono-, di-, and trimethylation of H3K4 [11,28]. Similarly, SMYD2
can mono-methylate H3K4 (H3K4me) and di-methylate H3K26 (H3K26me2) and p53K37me
[6,29]. In MZsmyd4L544Efs
1 mutants, H3K4me2 and H3K4me3 are reduced, suggesting that
smyd4 is a specific methyltransferase for H3K4 methylation. Notably, H3K4ac, K9ac, K14ac,
and K27ac were all abolished in the MZsmyd4L544Efs
1 mutants. This finding implies that the
deficiency of smyd4 impacts the function of hdac1 (the gene homologous to both HDAC1 and
HDAC2 in mammals). As previously demonstrated, cardiac-specific deletion of the mouse
Hdac1 and Hdac2 genes evoked a strong heart failure phenotype [20], which is consistent with
our finding. We are currently using biochemical approaches to determine whether smyd4
serves as a simple docking protein to provide chaperone functions for hdac1 or functions as a
key modulating molecule for hdac1. Nevertheless, our data suggest that smyd4 plays a critical
22), were dysregulated in MZsmyd4L544Efs
1 hearts; (C) KEGG pathway analysis revealed a major enrichment of upregulated genes in the endoplasmic reticulum-
mediated protein processing pathway; (D) KEGG pathway analysis revealed an enrichment of downregulated genes in pathways related to metabolic processes and
oxidative phosphorylation; (E) Gene Ontology (GO) terms of the biological processes (BP) associated with all differentially expressed genes. The up-regulated genes
function in organic substance metabolic processes, cardiovascular system development and embryonic organ development (p< 0.0001), while the downregulated genes
were enriched in the carbohydrate metabolic process, the glycolytic process, and the ATP metabolic process (p < 0.00001).
https://doi.org/10.1371/journal.pgen.1007578.g008
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role in the epigenetic regulation of gene expression via its dual activities as a methyltransferase
and negative regulator of hdac1.
RNA-seq analysis comparing wild-type and MZsmyd4L544Efs
1 mutant hearts demonstrates
that the expression of over 3,000 genes is altered, which may reflect the potential function of
smyd4’s broad epigenetic regulation of its target genes. In addition to genes related to cardiac
muscle contraction and cardiac signaling pathways that are highly relevant to cardiogenesis
(e.g., the canonical Wnt and Hedgehog signaling pathways) (Fig 8), our KEGG pathway and
GO annotation analyses of altered genes revealed an overwhelming enrichment in several cel-
lular metabolic pathways, including the endoplasmic reticulum-mediated protein processing
pathway. This finding is very different from the publicly available RNA-seq database for zebra-
fish heart developmental defects [30–32]. This finding suggests that smyd4 has a unique and
specific biological function in regulating cellular metabolism. However, as it is technically diffi-
cult to perform ChIP-seq on zebrafish embryonic hearts, we cannot currently determine
which specific components of the pathways are primarily affected and which are affected sec-
ondarily. Our future study will switch to a mammalian system to determine the detailed
molecular mechanism by which SMYD4 modulates cellular metabolism or signaling pathways
via its important role in epigenetic regulation. We will re-evaluate whether these altered meta-
bolic pathways play critical roles in cardiac development and the cardiac defects seen in smyd4
mutant embryos.
This study is the first characterization of SMYD4 in vertebrate development and physiologi-
cal function. Taken together, our results demonstrate the critical role of smyd4 in embryonic
development and heart formation. Our data suggest that smyd4 functions as a histone methyl-
transferase and, by interacting with HDAC1, also serves as a potential modulator for histone
acetylation. In addition, our work has also provided genetic and functional evidences that rare
SMYD4 variants likely contribute to CHDs.
Materials and methods
Ethics statement
All genetic studies were approved by the Ethics Committee of the Children’s Hospital of
Fudan University, China. The approval number is: [2015]92). All patients provided written
informed consent in accordance to the Declaration of Helsinki. The Research Ethics Commit-
tee of the Children’s Hospital of Fudan University, China, approved and monitored all zebra-
fish procedures following the guidelines and recommendations outlined by the Guide for the
Care and Use of Laboratory Animals. The approval number is: [2015]92). For all experiments,
wild-type zebrafish embryos of the Tu and transgenic Tg (cmcl2:GFP) (cardiac myosin light
chain 2:GFP reporter) strains were used.
In situ hybridization
The expression of smyd4 was detected in zebrafish embryos from the 10 to 72 hpf stages using
a smyd4-specific antisense probe. The template for the smyd4 probe was amplified from the
cDNA of zebrafish at 24 hpf. The 508-bp fragment, which was obtained using specific primers
(smyd4-probe-F: GAAGTGTGTGAAATGTGGAAAGCCTCTT and smyd4-probe-R: TTCA
CTCAGTTCCTGCAGTTCTTCACAG), was cloned into the pEasy-T vector (Promega, USA).
After linearization of the plasmids, the antisense and sense probes were transcribed and
labelled with digoxigenin in vitro. RNA in situ hybridization was performed as described
previously [33]. Briefly, zebrafish embryos at different stages were collected and fixed in 4%
paraformaldehyde at 4˚C overnight. Embryos older than 24 hpf were digested by proteinase K
at room temperature. Then, the embryos were pro-hybridized at 65˚C for 4 hours and
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subsequently incubated with the antisense or sense probes overnight. An anti-digoxigenin
antibody (Roche, USA) was used to bind the probes overnight at 4˚C. Finally, the embryos
were stained with NBT/BCIP (Vector, USA) and photographed in methylcellulose using a
Leica M205C microscope.
Zebrafish RNA preparation and qRT-PCR
Embryos of the wild-type Tu zebrafish strain were collected at 0.2, 2, 4, 8, 10, 24, 48 and 72 hpf.
The total RNA was extracted using the TRIzol reagent (Invitrogen, USA) and converted to
cDNA using the PrimeScript RT Reagent Kit (Takara Bio, Japan). The real-time qPCR reac-
tions were performed with SYBR Premix Ex Taq (Takara Bio, Japan) using the Roche 480 plus
system (Roche, USA). The real-time primers for the zebrafish are summarized in S4 Table.
Generation of smyd4 mutant zebrafish lines
smyd4 target sites were designed using the website http://zifit.partners.org/ZiFiT/CSquare9
Nuclease.aspx. The provided sites were then screened in Ensemble. Three sites that specifically
recognize the sequence of smyd4 in the zebrafish genome were chosen for the interruption of
smyd4. sgRNA1 (GGAGTAATGAAGCACTGCTG), sgRNA2 (GGAGCTGATCTGCTGGC
CAT), and sgRNA3 (GGAGCGTCAGCGCCTCCTGC) targeted exons 2, 4 and 6 of smyd4,
respectively. We cloned these sites into the gRNA plasmid p-T7-gRNA, which was provided by
Professor Li Qiang. gRNAs were transcribed in vitro using the MAXIscript T7 kit (Ambion,
USA). Cas9 mRNA was transcribed from the pSP6-2Snls-spCas9 plasmid using the SP6 mMES-
SAGE mMACHINE Kit (Ambion, USA), and poly A tails were added using the poly A Tailing
Kit (Ambion, USA). All gRNAs and the Cas9 mRNA were purified and dissolved in nuclease-
free water before injection using the mirVana miRNA Isolation Kit (Ambion, USA) and the
RNA Purification Kit (TIANGEN, China). gRNA and Cas9 mRNA were co-injected into the
embryos at the single-cell stage. Twenty injected embryos were used to identify the efficiency,
and the remaining embryos were raised to adulthood to obtain the mosaic founders. These
mosaic fish were crossed with wild-type zebrafish to produce heterozygotes, which were geno-
typed using Sanger sequencing methods. To analyze the cardiac defects in MZsmyd4L544Efs
1
mutants, we crossed the smyd4L544Efs
1 line to the cardiomyocyte-specific transgenic reporter
line Tg (cmcl2:GFP). All primers and target sites of smyd4 are summarized in S4 Table.
Cardiac phenotype analysis of the MZsmyd4 L544Efs
1 line
Embryos were collected at 48, 72, and 96 hpf for phenotype analysis. The embryos were
fixed in methylcellulose and imaged using Leica M205C and Leica SP8 microscopes (Leica,
Germany). To determine the number of cardiomyocytes in the developing ventricle, the
embryonic hearts at 96 hpf were carefully collected and scanned using Leica SP8 confocal
microscope. The z-step was set at 1μm. The images with largest section of ventricles were cho-
sen for the analysis. DAPI and EGFP double positive cells were scored for cardiomyocyte.
Adult fish at 6 months of age were photographed to record the body size and the developmen-
tal states of different organs, including the head, eyes, fins, and tails. These fish were dissected
after anesthesia. The hearts of adult zebrafish were fixed and photographed in 4% paraformal-
dehyde. Serial sectioning with H&E staining was performed for these heart samples.
Proliferation and apoptosis assays
Embryos were collected at 48 hpf, fixed in 4% paraformaldehyde at 4˚C overnight. For the pro-
liferation assay, the embryos were digested using Collagenase, Type II (Life technologies,
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USA) at room temperature, and blocking was performed for one hour at room temperature,
and followed by incubating with the primary antibody against p-H3(S10) (Abacam, USA) or
PCNA (Genetex, USA) at 4˚C overnight. Second antibody were from the series of Alexa Fluor
(Life technologies, USA). For the apoptosis assay, In Situ Cell Death Detection kit, TMR red
(Roche, USA) was used and all procedures were performed as the instruction manual
described. Finally, embryo hearts were collected under a Leica M205C stereomicroscope and
were imaged using a Leica SP8 microscope.
Plasmid construction and protein-protein interaction identification
A plasmid containing wild-type human SMYD4(BC035077) was obtained from Abmgood
(Abmgood, USA). Then, Flag-tagged wild-type SMYD4 and HA-tagged wild-type HDAC1
were cloned into the expression plasmid. The mutation (G345D) identified in patients was
obtained using the KOD-Plus Mutagenesis Kit (Toyobo, Japan). All plasmids were confirmed
via Sanger sequencing. The anti-SMYD4 (Proteintech, USA), anti-HDAC1 (Proteintech,
USA), anti-Flag (Abmart, China), and anti-HA (Abmart, China) antibodies were used. Wild-
type SMYD4 was overexpressed in HL-1 cells. After 48-h transfections, cell lysates were
obtained in RIPA containing 1 mM PMSF and complete protease inhibitors (Roche, USA).
Immunoprecipitation was performed using an anti-Flag affinity gel (Biotool, USA).
SDS-PAGE was performed to resolve the eluates. After sliver staining, the proteins underwent
mass spectrometry analysis. Protein-protein interactions were verified in HL-1 cells after tran-
sient overexpression of SMYD4. Co-immunoprecipitation was performed to confirm the
interaction between SMYD4 and HDAC1 in HEK293T cells using anti-tag antibodies.
Domain mapping and mutant protein analysis
HEK293T cells were transiently co-transfected with pCDH-Flag-SMYD4 deletion mutants
and pcDNA3-HA-HDAC1. Plasmids of SMYD4 were co-transfected into HEK293T cells, and
cell extracts were prepared as described above. Immunoprecipitations were performed with
anti-HA affinity beads (Biotool, USA). The beads were washed five times, and bound proteins
were eluted in SDS-PAGE loading buffer and analyzed via western blotting.
Immunofluorescence
Briefly, the immunofluorescence process is described as follows. The cells were fixed in 4%
paraformaldehyde and then underwent cell permeation and blocking. The antibody used for
immunofluorescence was anti-SMYD4 (Proteintech, USA). Primary antibodies were incu-
bated overnight at 4˚C. Secondary antibodies were from the Alexa Fluorescence Series (Life
technologies, USA). Finally, the cells were imaged in Diamond anti-fade agent (Life technolo-
gies, USA) using a Leica SP8 microscope.
Zebrafish western blotting and antibodies
Tg(cmcl2:GFP) and MZsmyd4L544Efs
1 embryos were collected at 48 hpf. Protein was obtained
in RIPA containing 1 mM PMSF and complete protease inhibitors (Roche, USA) after sonica-
tion. The histone modification antibodies used in this study include anti-H3 (CST, USA),
anti-H3K4ac (Active Motif, USA), anti-H3K9ac (Active Motif, USA), anti-H3K14ac (Active
Motif, USA), anti-H3K27ac (Active Motif, USA), anti-H3K4me1 (Active Motif, USA), anti-
H3K4me2 (Active Motif, USA), anti-H3K4me3 (Abcam, USA), anti-H3K9me3 (Abcam,
USA), and anti-H3K27me3 (Millipore, USA).
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Human samples and ethics statement
This study was approved by the research ethics committee of the Children’s Hospital of Fudan
University in Shanghai, China (number: [2015]92). The diagnosis of CHD patients was based
on echocardiography at the Children’s Hospital of Fudan University in Shanghai, China. All
patients involved in this research had not been diagnosed with extra cardiac anomalies and did
not have common chromosomal anomalies, such as the 22q11 microdeletion. Human cardiac
tissue samples from CHD patients were obtained from the Biobank of the Children’s Hospital
of Fudan University in Shanghai, China. Cardiac tissues were removed from the blocked right
ventricular outflow tract during surgery. All tissue samples were maintained in RNAlater RNA
Stabilization Solution (Thermo Scientific, USA) after surgery and stored at -80˚C before use.
RNA was extracted from the tissue samples using the Trizol reagent (Invitrogen, USA) and
immediately underwent reverse transcription using the PrimeScript RT Reagent Kit (Takara,
Japan). All detailed patient information is summarized in S2 Table.
Human genomic sequencing studies and in silico analysis
The peripheral venous blood samples from 113 patients were prepared for DNA extraction
using the Blood Extraction Kit (QIAGEN, Germany). The cardiac tissue samples from 95
patients were prepared for cDNA extraction. All of the regions covered by TES and all primers
for smyd4 exon sequencing in cDNA are listed in S5 Table. Variant analysis was performed
using the Mutation Surveyor software (Softgenetics, USA). All variants were screened in public
databases, including the 1000 Genome database, the dbSNP database, and the ExAC database,
and an internal database in the molecular diagnosis laboratory at the Children’s Hospital of
Fudan University. A risk analysis of SNVs was performed using SIFT, Polyphen2, and Muta-
tion Taster to predict the possible effects on protein function. A 3D structure analysis of the
wild-type and mutant proteins was performed on the SWISS MODEL website (https://www.
swissmodel.expasy.org/).
Microinjection of wild-type or mutant smyd4 mRNA (G295D) and
phenotype analysis
Based on its pathogenic prediction, the G345D SMYD4 variant was selected for mutation anal-
ysis. Homology analysis showed that the mutant G295D in smyd4 was equivalent to the mutant
G345D in SMYD4. The template for smyd4 wild-type mRNA transcription was amplified from
zebrafish cDNA at 24 hpf. The template of the mutant (G295D) in smyd4 transcription was
obtained using the KOD-Plus Mutagenesis Kit (Toyobo, Japan). The wild-type and mutant
mRNAs of smyd4 were transcribed using the mMessage mMachine T7 Ultra Kit (Ambion,
USA), and poly A tails were added using the poly A Tailing Kit (Ambion, USA), according to
the instruction manual. The mRNAs were resolved in nuclease-free water and finally quanti-
fied to 150 ng/μl for microinjection. Embryos of Tg(cmcl2:GFP) and MZsmyd4 L544Efs
1 were
collected. A total of 3 nl of mRNA was microinjected into embryos at the single-cell stage. Fifty
embryos from each group with cardiac GFP at 48 hpf were chosen for phenotype analysis. The
embryos were fixed in 3% methylcellulose after anesthetization and then observed for cardiac
morphology using a Leica M205C stereomicroscope.
RNA sequencing
Heart tissue was collected from 50 MZsmyd4L544Efs
1 or Tg(cmcl2:GFP) embryos. Cardiac-spe-
cific GFP helped us successfully obtain embryo heart tissue. Embryo hearts were collected at
72 hpf after anesthesia using a Leica M205C stereomicroscope. In-depth RNA sequencing was
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performed by the Novogene Experimental Department in China. The raw sequencing image
data were examined via the Illumina analysis pipeline and aligned with the unmasked zebrafish
reference genome. Differential expression analysis of the two groups was performed using the
DESeq2 R package (1.10.1). The resulting P-values were adjusted using the Benjamini and
Hochberg’s approach for controlling the false discovery rate. Genes with an adjusted P-
value < 0.005 and |log2 (Fold change)|>1 found by DESeq2 were assigned as differentially
expressed.
Statistical analyses
The Student’s t-test was used for all statistical analyses. A p-value of< 0.05 (2-sided) was
regarded as statistically significant. All experiments were repeated three times. All data were
analyzed with GraphPad Prism (version 5.0).
Supporting information
S1 Fig. Genotyping of MZsmyd4L544Efs
1 mutants. An 11-nt insertion was achieved using the
CRISPR-Cas9 technology and was validated by cDNA PCR and sequencing analyses in
MZsmyd4L544Efs
1.
(TIF)
S2 Fig. Heterozygous breeding scheme generated some abnormal cardiac situs ambiguus
and hypoplastic hearts in homozygous and heterozygous mutants.
(TIF)
S3 Fig. Representative images for analyzing the number of cardiomyocytes in
MZsmyd4L544Efs
1 mutant and control hearts. The confocal images of the largest section of
the ventricle of MZsmyd4 L544Efs
1 and Tg(cmcl2:GFP) hearts at 96 hpf.
(TIF)
S4 Fig. The PCNA immunofluorescence staining showed decreased cell proliferative activ-
ity in MZsmyd4L544Efs
1 cardiomyocytes at 48 hpf.
(TIF)
S5 Fig. Cellular apoptosis was not seen in the MZsmyd4L544Efs
1 ventricles at 48 hpf.
TUNEL assays showed that there is no apoptosis in neither control hearts and
MZsmyd4L544Efs
1 hearts (Upper panel). The positive TUNEL signals (red fluorescence) in the
tail fin and embryos at 48 hpf treated with DNase I were used as positive controls for the analy-
sis (Lower panel).
(TIF)
S6 Fig. Confocal images of fluorescence immunostaining of actin1a, co-stained with DAPI.
The skeletal muscle structures of MZsmyd4L544Efs
1 mutants appeared to be normal at 72 hpf.
(TIF)
S7 Fig. Schematic domain alignment and homology between the human and zebrafish
SMYD4 proteins. Both human SMYD4 and the zebrafish smyd4 protein have four functional
domains, including 2 TPR domains, one MYND domain, and one SET domain. These
domains are highly conserved between the two species. The two rare variants identified in
CHD patients are located at the edge of the MYND and SET domains. Zebrafish smyd4
(G295D) is equivalent to human SMYD4(G345D).
(TIF)
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S1 Table. Clinical characteristics of CHD patients.
(DOCX)
S2 Table. Detailed CHD patient information.
(XLSX)
S3 Table. Information regarding the rare variants identified in the CHD patients.
(DOCX)
S4 Table. Primers used for qPCR, CRISPR/Cas9 construction, and genotyping in zebra-
fish.
(XLSX)
S5 Table. All of the regions covered by TES and sequencing primers for Sanger sequencing.
(XLSX)
S1 Movie. 3D reconstruction of hearts in Tg(cmcl2:GFP) embryos.
(MP4)
S2 Movie. 3D reconstruction of hearts in MZsmyd4 L544Efs
1.
(MP4)
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